Nephrotoxicity Clinical Trial
Official title:
Drug Disposition and Nephrotoxicity
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | December 31, 2026 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Male or female patient prescribed cisplatin at a dose of >25 mg/m^2 - Age 18-80 years - Hemoglobin >/=10 g/dl - No consumption of grapefruit juice or alcohol within 7 days - No history of alcohol consumption of >14 drinks/week - No history of organ transplantation or kidney dialysis - Willingness to comply with study - Not pregnant or lactating - No changes in chronic medications within 2 weeks - Estimated glomerular filtration rate (eGFR) > 60 ml/min^2 - Normal liver function (ALT and AST <2x ULN) Exclusion Criteria: - Diagnosis of kidney cancer - Previous exposure to platinum-based chemotherapy - Herbal supplement use beyond marijuana - Exposure to other known nephrotoxins (including contrast agents) within the previous 2 weeks - Concurrent use of competitive inhibitors of transport proteins (metformin, cimetidine, ranitidine, antiviral drugs, cephalosporins, topotecan, methotrexate, vinblastine) - Severe gastrointestinal disease with fluid losses - Diagnosis of a rapidly progressive glomerulonephritis - Allergy or contraindication to 5-HT3 Antagonists |
Country | Name | City | State |
---|---|---|---|
United States | UCHealth-Metro Denver | Denver | Colorado |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | Memorial Sloan Kettering Cancer Center, National Institute of General Medical Sciences (NIGMS), Rutgers University |
United States,
Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22;18(7):1333. doi: 10.3390/ijms18071333. — View Citation
George B, Joy MS, Aleksunes LM. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood). 2018 Feb;243(3):272-282. doi: 10.1177/1535370217745302. Epub 2017 Dec 12. — View Citation
George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity. Clin Pharmacol Ther. 2017 Apr;101(4):510-518. doi: 10.1002/cpt.606. Epub 2017 Feb 14. — View Citation
George B, You D, Joy MS, Aleksunes LM. Xenobiotic transporters and kidney injury. Adv Drug Deliv Rev. 2017 Jul 1;116:73-91. doi: 10.1016/j.addr.2017.01.005. Epub 2017 Jan 20. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Kidney Injury with Cisplatin and 5-HT3 Antagonist Antiemetic Regimen as Assessed by a 1.5 fold increase in a Biomarker Panel | The effects of 5-HT3 antagonist antiemetic drugs on cisplatin kidney injury as indicated by a 1.5 fold increase in the urinary biomarker panel values at 3 days after treatment | 3 days | |
Primary | The Effects of 5-HT3 Antagonist Antiemetic Drugs on Cisplatin Secretion | The changes to cisplatin secretion in the urine (as an early biomarker for the detection of kidney injury) as indicated by a 6 mg difference between 5-HT3 Antagonist Antiemetic Drugs at 3 days after treatment | 3 days | |
Secondary | Targeted Genetic Polymorphisms are Associated with Risk of Kidney Injury Due to Cisplatin and 5-HT3 Antagonist Antiemetic Regimen as Assessed by a 1.5 fold increase in a Biomarker Panel | The influence of targeted genetic polymorphisms on risk of kidney injury due to cisplatin and 5-HT3 Antagonist Antiemetic Drugs as indicated by a 1.5 fold increase in a urinary biomarker panel values at 3 days after treatment | 3 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06360666 -
Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
|
||
Recruiting |
NCT01624324 -
Aminoglycoside Plasma Level Measurement in Neonates With Infection
|
N/A | |
Completed |
NCT01216540 -
Vancomycin-Associated Nephrotoxicity
|
||
Completed |
NCT01467154 -
Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center
|
N/A | |
Recruiting |
NCT03480971 -
Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
|
Phase 2 | |
Recruiting |
NCT02528448 -
0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis
|
Phase 4 | |
Completed |
NCT02103855 -
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06153147 -
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)
|
||
Completed |
NCT04354467 -
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
|
||
Recruiting |
NCT05673824 -
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
|
Phase 4 | |
Not yet recruiting |
NCT03438214 -
Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients
|
Phase 4 | |
Completed |
NCT03527160 -
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
|
||
Completed |
NCT01848457 -
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
|
Phase 2 |